Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight[Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open- label Phase 3b clinical trial...]### Lilly to participate in TD Cowen's 46th Annual Health Care Conference[Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice...][More Releases From This Source]## Explore[He ...